Synaptogenix (SNPX) Competitors $7.12 -1.08 (-13.17%) As of 07/9/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. EGRX, GRCE, XCUR, ACRV, ARTV, ELYM, MRSN, BRNS, STTK, and ITRMShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Eagle Pharmaceuticals (EGRX), Grace Therapeutics (GRCE), Exicure (XCUR), Acrivon Therapeutics (ACRV), Artiva Biotherapeutics (ARTV), Eliem Therapeutics (ELYM), Mersana Therapeutics (MRSN), Barinthus Biotherapeutics (BRNS), Shattuck Labs (STTK), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors Eagle Pharmaceuticals Grace Therapeutics Exicure Acrivon Therapeutics Artiva Biotherapeutics Eliem Therapeutics Mersana Therapeutics Barinthus Biotherapeutics Shattuck Labs Iterum Therapeutics Synaptogenix (NASDAQ:SNPX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Is SNPX or EGRX more profitable? Eagle Pharmaceuticals' return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -115.28% -58.31% Eagle Pharmaceuticals N/A N/A N/A Does the media prefer SNPX or EGRX? In the previous week, Synaptogenix and Synaptogenix both had 1 articles in the media. Synaptogenix's average media sentiment score of 1.87 beat Eagle Pharmaceuticals' score of 0.00 indicating that Synaptogenix is being referred to more favorably in the media. Company Overall Sentiment Synaptogenix Very Positive Eagle Pharmaceuticals Neutral Do institutionals and insiders believe in SNPX or EGRX? 10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, SNPX or EGRX? Synaptogenix has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Which has better earnings & valuation, SNPX or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than Synaptogenix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenixN/AN/A-$12.77M-$10.08-0.71Eagle Pharmaceuticals$257.55M0.18$35.64MN/AN/A SummaryEagle Pharmaceuticals beats Synaptogenix on 6 of the 8 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.90M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E Ratio-0.717.5819.7619.92Price / SalesN/A292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book1.647.638.045.49Net Income-$12.77M-$55.05M$3.18B$250.27M7 Day Performance-16.24%8.54%3.72%4.78%1 Month Performance39.88%5.38%3.72%7.20%1 Year Performance63.30%2.35%29.92%17.27% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenix0.0459 of 5 stars$7.12-13.2%N/A+66.0%$9.90MN/A-0.714Positive NewsGap DownEGRXEagle Pharmaceuticals2.608 of 5 stars$3.25+8.3%N/A-41.2%$42.21M$257.55M0.00100News CoverageGRCEGrace Therapeutics2.5783 of 5 stars$3.04+1.3%$12.00+294.7%N/A$41.49MN/A-3.42N/AHigh Trading VolumeXCURExicure1.5476 of 5 stars$6.95+7.4%N/A+2,279.1%$40.88M$500K-1.8250Positive NewsGap DownACRVAcrivon Therapeutics3.4406 of 5 stars$1.31+4.8%$17.71+1,252.2%-81.1%$39.19MN/A-0.5958Positive NewsARTVArtiva Biotherapeutics3.0649 of 5 stars$1.69+7.0%$17.80+953.3%N/A$38.49M$250K0.0081ELYMEliem TherapeuticsN/A$1.28+1.6%N/A-81.2%$38.08MN/A-2.429MRSNMersana Therapeutics4.0477 of 5 stars$0.33+7.5%$5.20+1,490.2%-80.6%$37.92M$40.50M-0.55150Gap UpBRNSBarinthus Biotherapeutics2.9983 of 5 stars$0.99+6.2%$6.25+534.5%-26.1%$37.41M$14.97M-0.60107Positive NewsSTTKShattuck Labs3.7419 of 5 stars$0.81+4.8%$7.50+826.6%-79.1%$36.98M$5.72M-0.58100Positive NewsITRMIterum Therapeutics2.0046 of 5 stars$0.93+1.0%$9.00+864.6%-26.5%$36.95MN/A-0.9410 Related Companies and Tools Related Companies Eagle Pharmaceuticals Alternatives Grace Therapeutics Alternatives Exicure Alternatives Acrivon Therapeutics Alternatives Artiva Biotherapeutics Alternatives Eliem Therapeutics Alternatives Mersana Therapeutics Alternatives Barinthus Biotherapeutics Alternatives Shattuck Labs Alternatives Iterum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.